Evaluation of the Efficacy and Safety of AFQ056 in Parkinson's Patients With L-dopa Induced Dyskinesias

Completed · Phase 2 · Has a placebo group

Conditions studied: Dyskinesias, Parkinson Disease, Movement Disorders, Parkinsonian Disorders

In brief

This study will assess the efficacy and safety of AFQ056 in patients that have Parkinson's Disease L-dopa Induced Dyskinesias (PD-LID)

Key facts

Study ID

NCT01385592

Run by

Novartis Pharmaceuticals

People needed

78

Starts

2011-11-01

Expected to finish

2012-09-01

Last updated by the study team

2020-12-23

Who can join

Age: 30 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Outpatients with Parkinson's disease (PD), treated with L-Dopa, experiencing dyskinesias for at least three months
• Outpatients who are on a stable anti-parkinsonian treatment regimen for at least four weeks

You may not qualify if…

• Surgical treatment for PD
• Cancer within the past 5 years (other than localized skin cancer and prostate cancer that has been effectively treated)
• Advanced, severe or unstable disease (other than PD) or evidence of dementia that may interfere with the study outcome evaluations
• Other protocol-defined inclusion/exclusion criteria may apply

Where it is running

• Novartis Investigative Site — Sunnyvale, California, United States
• Novartis Investigative Site — Englewood, Colorado, United States
• Novartis Investigative Site — London, Ontario, Canada
• Novartis Investigative Site — Gatineau, Quebec, Canada
• Novartis Investigative Site — Clermont-Ferrand, France
• Novartis Investigative Site — Lille, France
• Novartis Investigative Site — Pessac, France
• Novartis Investigative Site — Poitiers, France
• Novartis Investigative Site — Beelitz-Heilstätten, Germany
• Novartis Investigative Site — Berlin, Germany
• Novartis Investigative Site — Bochum, Germany
• Novartis Investigative Site — Düsseldorf, Germany
• Novartis Investigative Site — Kassel, Germany
• Novartis Investigative Site — Leipzig, Germany
• Novartis Investigative Site — München, Germany
• Novartis Investigative Site — München, Germany
• Novartis Investigative Site — Stadtroda, Germany
• Novartis Investigative Site — Westerstede/Oldenburg, Germany
• Novartis Investigative Site — Budapest, Hungary
• Novartis Investigative Site — Kaposvár, Hungary
• Novartis Investigative Site — Szeged, Hungary
• Novartis Investigative Site — Bolzano, BZ, Italy
• Novartis Investigative Site — Pisa, PI, Italy
• Novartis Investigative Site — Roma, RM, Italy
• Novartis Investigative Site — Sant Cugat del Vallès, Barcelona, Spain

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.